
BUSINESS
FINLAND
eHEALTH
8 Jan 2019
Horizon 2020 & IMI2
Non-confidential

BUSINESS
FINLAND

WHAT & WHY
FUNDING & NETWORKS

Structure of Horizon 2020

I Excellent Science

1. European Research Council (ERC): frontier research
2. Future and Emerging Technologies (FET).
   a) Open

24 bn€

3. Marie Skłodowska-Curie (MSCA) – actions:
   training, career development and mobility for researchers
4. Research Infrastructures

II Industrial Leadership

1. Leadership in Enabling and Industrial Technologies
   - 1.1. ICT
   - 1.2. nanotechnology
   - 1.3. materials
   - 1.4. biotechnology
   - [illegible]turing and

17 bn€

2. Risk finance:
   loans & equity funding
3. Innovation in SMEs

20% of the budget or pillars II + III to SMEs
- SME Instrument(1/3)
- Collaborative projects (2/3)

III Societal Challenges

1. Health, demographic change and wellbeing
2. Food security, sustainable agriculture and forestry, marine, maritime and inland water research and bioeconomy
3. Secure, clean and efficient energy
   [illegible]d integrtaed

30 bn€

5. Climate action, resource efficiency and raw materials
6. Europe in a changing world: inclusive, innovative and reflective societies
7. Secure societies – protecting freedom and security of Europe and its citizens

Also: European institute of innovation and technology, Science with and for society, Spreading excellence and widening participation

IV Joint Research Center JRC, excl. nuclear

Nuclear research: EURATOM

HORISONTTI 2020
EU:n tutkimus- ja innovaatio-ohjelmat

BUSINESS FINLAND

National Contact Points (NCPs) for H2020 Health

Pekka Rantala

Business Finland
pekka.rantala@businessfinland.fi
+358 50 396 2922

Vera Mikkilä

Academy of Finland
vera.mikkila@aka.fi
+358 29 533 5048

BUSINESS FINLAND

Do I Get Funding Also?

- ✓Best expertise for your business case at European level.
- ✓Solid strategy, growth vision and committed capabilities.
- ✓Company wants to try a risky, radical or disruptive innovation which requires extensive R&D collaboration (typically min. 3 participants from 3 countries) before full commercialization.
- ✓Big business case scenario is planned in 3-5 or 5-8 yr ahead.
- ✓If successful the business case could bring dozens or hundreds of millions of turnover for your company and possibly extra turnover in different industries as well.

BUSINESS
FINLAND

Why Should I Care?

- ✓Leveraged public risk funding (for companies) as 70/100 % grants (+25%).
- ✓Funding for small projects €50k/€2.5M (SME-1&2) and for a small consortium €2-4M. Large projects are typically €5-8M, pilot grades €10-40M.
- ✓Create direct R&D and selling contacts.
- ✓Possibility to find, work and develop with the best academic and industry expertise. Get access to (possibly) hard to find Intellectual Property (e.g. patents, data, algorithms).

HOW
TRLs & CALL TYPES

BUSINESS
FINLAND

Technology Readiness Levels [Academic + Applied Research]

TRL 1 – Basic principles observed.

TRL 2 – Technology concept formulated.

TRL 3 – Experimental proof of concept.

<!-- Companies' R&D starts from here -->

TRL 4 – Technology validated in lab.

TRL 5 – Technology validated in relevant environment.

BUSINESS
FINLAND

Technology Readiness Levels [Applied + Industrial R&D&I]

TRL 6 – Technology demonstrated in relevant environment.

TRL 7 – System prototype demonstration in operational environment.

TRL 8 – System complete and qualified.

<!-- Companies' R&D ends here -->

TRL 9 – Actual system proven in operational environment.

BUSINESS
FINLAND

TOP 4 Call Types 4 Companies (=Where The Money Is)

Bottom-up | Commercial Time Horizon <3 yr | 70 % grant

* SME Instrument I/II: TRL 6-9 (~BF | Tempo/YIC)
* Fast Track to Innovation: TRL ~6-9 (~BF | R&D/Co-Innovation)

Top-down | Commercial Time Horizon ~3-5 yr | 70 % grant

* Innovation Action (IA): TRL ~6-8 (~BF | Co-Innovation)

Top-down | Commercial Time Horizon ~5-8 yr | 100 % grant

* Research and Innovation Action (RIA): TRL ~4-6 (~AoF+VTT)

BUSINESS
FINLAND

APPENDIX
BOTTOM-UP FUNDING

BUSINESS
FINLAND

SME Instrument – Phase I

Fully-bottom-up innovation support for a SME with funding rate of 70 %. Promotes a radically new idea underpinned by a business plan for rolling out marketable innovation solutions and with ambitions to scale up.

Phase I: A lump sum of €50 k for 6 months.

-> Study R&D, technical feasibility and commercial potential of a ground-breaking, innovative idea and develop it into a credible business plan for scaling it up.

BUSINESS
FINLAND

SME Instrument – Phase II

Phase II: Project funding of €0.5-2.5M for 12-24 months.

-> Develop business concept further into a market-ready product, service or process aligned with your company's growth strategy. Activities could, for example, include trials, prototyping, validation, demonstration and testing in real-world conditions, and market replication. If the activity concerns a primarily technological innovation, a Technology Readiness Level (TRL) of 6 or above is envisaged.

BUSINESS
FINLAND

Fast Track to Innovation (FTI)

Fully-bottom-up innovation support programme promoting close-to-the-market innovation activities open to industry-driven consortia that can be composed of all types of participants. It can help partners to co-create and test breakthrough products, services or business processes that have the potential to revolutionize existing or create entirely new markets.

* 3-5 legal entities | 70 % grant (+25 %) | EUR 3M.
* Majority of the funding to industry (E.g. min. 60 % OR industry partners in the same consortium: 2/(3-4) or 3/5.

BUSINESS
FINLAND

APPENDIX
TOP-DOWN FUNDING [MAIN eHEALTH CALLS]

BUSINESS
FINLAND

SC1-BHC-13-2019: RIA €12-15M

Mining big data for early detection of infectious disease threats driven by climate change and other factors.
Specific Challenge: The use of next generation sequencing combined with surveillance data, health registries and societal data from informal/non-traditional sources (e.g. social media).
Scope: 1. The technology to allow the pooling, access, analysis and sharing of relevant data (incl. including next generation sequencing); 2. The innovative bio-informatics and modelling methodologies that enable risk modelling and mapping; 3. The analytical tools for early warning, monitoring, risk assessment.

BUSINESS
FINLAND

SC1-DTH-01-2019: RIA €3-5M

Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment.

Specific Challenge: In addition to patient reported outcomes such as functional status, symptoms intensity and frequency, multiple domains of well-being and overall satisfaction with life, the use of big data can bring valuable information for monitoring health status and quality of life after the cancer treatment.

Scope: How to better acquire, manage, share, model, process and exploit big data using, if appropriate, high performance computing to effectively monitor health status.

BUSINESS
FINLAND

SC1-DTH-05-2019: PPI €2-5M

Large scale implementation of digital innovation for health and care in an ageing society.

Specific Challenge: An ageing population is increasing demand-side pressures on public health and social care providers across Europe.

Scope: To the Scale-Up Strategy of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) and will support the EIP on AHA Reference Sites contribution to the Digital Single Market Strategy.

BUSINESS
FINLAND

SC1-DTH-09-2019: IA €5-8M

Scaling up the univocal Identification of Medicinal Products.
Specific Challenge: Across the European Union, medicinal products display differences in names, variations in strength or their package size.
Scope: Two goals: (i) the cross-border mobility of European patients by offering safer eDispensations across borders, (ii) the implementation of the IDMP (identification of medicinal products) standards in Member States drug databases. This requires creating an EU ePrescription/eDispensing approach to use the future EU SPOR database.

BUSINESS
FINLAND

SC1-DTH-10-2019-2020: PCP €5-6M

Digital health and care services.

Specific Challenge: Digital solutions supporting a continuum of care across a range of health and care services can relieve the pressure on governments to provide more cost-effective health and care systems by improving utilisation of healthcare and health outcomes.

Scope: Support the health and care service provider to procure the development, testing and implementation of digital services and communication concepts that can facilitate the transition to integrated care models across health and social services.

BUSINESS
FINLAND

SC1-DTH-11-2019: IA €4-6M

Large Scale pilots of personalised & outcome based integrated care.

Specific Challenge: Senior people are statistically at greater risk of cognitive impairment, frailty and multiple chronic health conditions with consequences for independence, quality of life.

Scope: Foster the large-scale pilots for deployment of trusted and personalised digital solutions dealing with Integrated Care. Supporting and extending healthy and independent living for older individuals who are facing permanently or temporarily reduced functionality and capabilities.

BUSINESS
FINLAND

SC1-HCC-02-2019: CSA €1,5M

Support for the large scale uptake of open service platforms in the Active and Healthy Ageing domain.

Specific Challenge: The integration of platforms between different domains will introduce new interoperability issues that need to be tackled.

Scope: Proposals should deliver an inventory of the state of the art and analyse the use of open service platforms in the Active and Healthy Ageing domain, covering both open platforms -such as universAAL and FIWARE - and partly-open/proprietary platforms developed by industry.

BUSINESS
FINLAND

DT-TDS-01-2019: IA €15-20M

Smart and healthy living at home.
Specific Challenge: The challenge is to foster large-scale deployment of integrated digital solutions which will bring improved quality of life to citizens while demonstrating significant efficiency gains in health and care delivery across Europe.
Scope: A mix of advanced ICT ranging from biophotonics to robotics, from artificial intelligence to big data and from IoT to smart wearables can address these challenges. A platform for smart living at home should integrate these technologies in an intelligent manner.

APPENDIX
FORTHCOMING TOP-DOWN CALLS 2019-2020

BUSINESS
FINLAND

Personalized Medicine

SC1-BHC-06-2020: Digital diagnostics – developing tools for clinical decisions integrating in vitro and in vivo diagnostics.

SC1-HCO-01-2018-2019-2020: Actions in support of the International Consortium for Personalised Medicine.

SC1-HCO-03-2020: Improving EU-13 participation in EU-supported health research programmes.

BUSINESS FINLAND

Digital Transformation & Trusted Digital Solutions

SC1-DTH-02-2020: Personalised early risk prediction, prevention and intervention, RIA.

SC1-DTH-04-2020: International cooperation in digital solutions and robotics for independent living.

SC1-DTH-06-2020: Accelerating the uptake of in-silico methods for testing medicines with dermatological use.

SC1-DTH-10-2019-2020: Digital health and care services.

SC1-HCC-06-2020: Support to eHealth Innovation ecosystems in Europe.

BUSINESS FINLAND

Digital Transformation & Trusted Digital Solutions

SC1-HCC-07-2020: Support for European eHealth Interoperability roadmap deployment.

SC1-HCC-08-2020: Scaling up innovation for active and healthy ageing.

SC1-HCC-09-2020: Supporting deployment of eHealth in developing countries for better health outcomes.

DT-ICT-12-2020: The smart hospital of the future.

DT-TDS-04-2020: Demonstrating the potential and benefits of a European Digital Health Infrastructure for Personalised Medicine.

APPENDIX
INNOVATIVE MEDICINES INITIATIVE (IMI)

BUSINESS
FINLAND

EU Partnership for Health



imi innovative medicines initiative

BUSINESS FINLAND

About Next IMI2 Call

- ✓IMI2 – Call 17 webinars available on 23–31 Jan 2019: https://www.imi.europa.eu/news-events/events/imi2-call-17-webinars
- ✓Optimising future obesity treatment.
- ✓Open access chemogenomics library and chemical probes for the druggable genome.
- ✓Intelligent prediction and identification of environmental risks posed by human medicinal products.

BUSINESS
FINLAND

Long-term Future Topics

- ✓Indicative information of future calls (i.e. from IMI2 – Call 18 onwards):
  https://www.imi.europa.eu/apply-funding/future-topics

- ✓Further information:
  Eija-Riitta Hämäläinen
  +358 40 672 4294
  eija-riitta.hamalainen@businessfinland.fi

BUSINESS
FINLAND

WORLD **IDEAS**

Pekka Rantala

Senior Advisor | Growth Companies
Horizon 2020 NCP (eHealth, ICT & Cybersecurity)
+358 50 396 2922
pekka.rantala@businessfinland.fi
businessfinland.fi/en | horisontti2020.fi

BUSINESS
FINLAND

QUESTIONS
WELCOME

THANKS!